The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes
CLINICAL BIOCHEMISTRY, vol.48, no.18, pp.1264-1267, 2015 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 48 Issue: 18
- Publication Date: 2015
- Doi Number: 10.1016/j.clinbiochem.2015.08.001
- Journal Name: CLINICAL BIOCHEMISTRY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1264-1267
- Keywords: Sphingosine 1-phosphate, Diabetic nephropathy, Apoprotein M, Symmetric dimethylarginine, Asymmetric dimethylarginine, Albuminuria, ENDOTHELIAL BARRIER FUNCTION, ASYMMETRIC DIMETHYLARGININE, APOLIPOPROTEIN M, HDL, ADMA, PROGRESSION, METABOLISM, MECHANISM, MELLITUS, ALBUMIN
- Istanbul University Affiliated: Yes
Abstract
Objectives: Sphingosine 1-phosphate (S1P) is carried in plasma by the HDL particles and albumin. It mediates several protective functions of HDL. Because of its barrier-enhancing effect, it has attracted attention in diseases associated with endothelial dysfunction. We examined the impact of circulating levels of S1P in diabetic nephropathy together with apoprotein M, a S1P-binding protein in HDL. Plasma levels of dimethylarginines were evaluated in this context.